Earnings call
Aurobindo Pharma Q1 FY27 earnings call: Aurobindo Pharma Limited expects its tax rate to normalise around 28-29% by year-end
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company expects its tax rate to normalise around 28-29% by year-end. Production at Aurobindo Pharma Limited’s China OSD facility doubled over the past 12 months. Consolidated revenues increased 16% year-on-year to Rs. 9,150 crores in the first quarter ended June 30, 2026, driven by broad-based performance across its business area. The company has been able to produce 6-APA effectively, and its yield is in line with expectations. Net CapEx was $78 million in the first quarter ended June 30, 2026.
The numbers management gave
Results
- Consolidated revenues increased 16% year-on-year to Rs. 9,150 crores in the first quarter ended June 30, 2026, driven by broad-based performance across its business area.
Show source
• Our consolidated revenues increased by 16% year-on-year to Rs. 9,150 crores driven by broad-based performance across our business area.
- Operating EBITDA, excluding a one-time impact of Rs. 43 crores towards a loss on derecognition of leased residuals, stood at Rs. 1,924 crores with a margin of 21% in the first quarter ended June 30, 2026.
Show source
• Operating EBITDA, exploring one-time impact of Rs. 43 crores towards a loss on derecognition of leased residuals, stood at Rs. 1,924 crores with a margin of 21%.
- European business generated revenues of €267 million, with 11% year-on-year growth in constant currency terms, in the first quarter ended June 30, 2026.
Show source
• Our European business continued its strong trajectory with revenues reaching €267 million, delivering 11% year -on-year growth in constant currency terms.
- Growth Markets revenues increased 38% year-on-year to Rs. 1,063 crores or $113 million in the first quarter ended June 30, 2026, supported by strong underlying performance across key markets.
Show source
• Growth markets revenues increased by 38% year -on-year to Rs. 1,063 crores or $113 million, supported by strong underlying performance across key markets.
- ARV formulation revenues were $35 million for the first quarter ended June 30, 2026, unchanged from the comparison period, driven by stable volume.
Show source
• ARV formulation remained stable at $35 million for the quarter, driven by stable volume.
- Gross margin was 60.4% in the first quarter ended June 30, 2026, compared with 58.8% in Q1 FY26, benefiting from an improved business mix and operating efficiency.
Show source
3 Aurobindo Pharma Limited 06 August 2026 Operational and Financial highlights: Gross margin remained resilient at 60.4% compared to 58.8% of Q1 FY26, benefiting from an improved business mix and operating efficiency.
Show 9 more statements
Results
- Gross contribution amounted to Rs. 5,523 crores in the first quarter ended June 30, 2026.
Show source
Our gross contribution amounted to Rs. 5,523 crores.
- R&D expenses were around Rs. 350 crores, amounting to 4% of revenues, in the first quarter ended June 30, 2026.
Show source
R&D expenses for the quarter is around Rs. 350 crores, amounting to 4% of the revenues.
- Average finance cost declined to 4.8% from 5% in the previous quarter, reflecting prudent treasury management, in the first quarter ended June 30, 2026.
Show source
Our average finance cost declined to 4.8% from 5% in the previous quarter, reflecting prudent treasury management.
- Net effective tax rate was 31.9% in the first quarter ended June 30, 2026, because it did not take the tax credit on loss-making subsidiaries.
Show source
Our net effective tax rate is 31.9% on account of not taking the tax credit on loss -making subsidiaries.
- Profit after tax stood at Rs. 1,032 crores in the first quarter ended June 30, 2026.
Show source
Profit after tax stood at Rs. 1,032 crores, reflecting a healthy operating leverage and efficient capital management.
- Lannett’s utilization was about 40%, and Aurobindo Pharma Limited plans to take it to a decent level under a 12-month plan, without disclosing the target percentage.
Show source
Swami Iyer: So, we have about 40 percent utilization and then we plan to take it to a decent level.
- The company achieved 20% Europe EBITDA, compared with single digit Europe EBITDA three or four years back, due to accelerated captive supply and cost reduction programs.
Show source
If you recollect, Shyam, we have been a single digit some three, four years back and Murali and the team as well as the accelerated captive supply and other things, cost reduction programs, etc. done by the team, we have achieved 20%.
Money and capital
- Net CapEx was $78 million in the first quarter ended June 30, 2026.
Show source
Net CapEx for the quarter stood at $78 million.
- The company had a net cash position of $42 million after paying $85 million towards buyback and $247 million for the Lannett acquisition in the first quarter ended June 30, 2026; including investments, it stood at USD 42mn as on 30-Jun-26.
Show source
Our balance sheet continues to remain strong with a strong net cash position of $42 million after payment of $85 million towards buyback and $247 million for Lannett acquisition, reinforcing our strong financial resilience and focus on various accretive growth opportunities while maintaining a disciplined capital structure.
What it expects ahead
What management expects
- The company expects its tax rate to normalise around 28-29% by year-end.
Show source
However, we expect the tax rate to normalise around 28 -29% by year-end.
- The company expects China to record positive EBITDA this year, compared with an EBITDA loss of around 7 million last year.
Show source
This year we should be doing better than, I mean, we should be doing positive.
- The company would like to see Lannett net sales of at least 60 million without the other product.
Show source
The net sale 60 million, that is what we would like to see at least without the other product.
- Unit 1 revenues will begin from 2028 if the customer wants stockpiling, and Unit 2 revenues will begin from 2031.
Show source
Satakarni Makkapati: So, as I told you, the Unit 1 revenues will begin from 2028 if the stockpiling is what the customer wants.
- The company expects Unit 1 and Unit 2 together to generate around US$150 to $200 million in 2032 as a good case for the contract manufacturing business.
Show source
So put together, Unit 1 and Unit 2, 2032, you should be looking at around US$150 to $200 million as a good case for the contract manufacturing business between Unit 1 and Unit 2.
- The company expects its R&D expense rate to continue at the current rate, driven by research costs towards the pipeline and the higher base of revenues.
Show source
We expect the current rate to continue, driven by research costs towards the pipeline and the higher base of revenues.
Show 5 more statements
What management expects
- The company expects slightly lower development costs in the upcoming period because multiple clinical studies are at an advanced stage.
Show source
Further, since multiple clinical studies are at an advanced stage, we expect slightly lower development costs for the upcoming period.
- The existing promoter, who is going to be CEO of the new company, has a vision of taking it to at least three to five X over a period of three to five years.
Show source
And he has a very big vision of taking it to at least three to five X in over a period of three to five years.
- The company expects to close FY27 with double digit growth over the previous year.
Show source
And FY27, definitely we are expecting to close with a double digit growth over the previous year.
- The company expects a steady revenue stream from TheraNym unit one beginning in 2028, anticipating customer stockpiling requirements ahead of launch; engineering and validation batches in 2027 will generate revenues; depending on the customer’s stockpiling efforts. Replaced by a later filing.
- The company expects a steady revenue stream from TheraNym unit one from 2028, depending on the customer’s stockpiling efforts. Replaced by a later filing.
What it is building and selling
Projects and capacity
- Production at Aurobindo Pharma Limited’s China OSD facility doubled over the past 12 months.
Show source
Further production at our China OSD facility doubled over past 12 months, making a significant milestone in the ramp-up of one of our strategic investments for sustained growth.
- PEN-G plant has been producing in the range of around more than 800 tonnes to 900 tonnes, which is converted into 6-APA and ultimately Amoxi.
Show source
S. Subramanian: So, the PEN-G plant, we have been continuously achieving a capacity of around more than 800 tonnes to 900 tonnes is the range we have been producing.
- The company inaugurated unit one of TheraNym on 3rd June, 2026, and remains on track to begin qualification activities for the facility and equipment by November 2026.
Show source
And we remain on track to begin qualification activities of the facility and the equipment by November 2026.
- Validation batches for the customer’s anchor product in unit one of TheraNym are scheduled in 2027, after which the customer will file the product from the site in the target markets.
Show source
The validation batches for the customer for the anchor product in unit one of TheraNym are scheduled in 2027, after which the customer will file the product from the sit e in the target markets.
- TheraNym unit two, a pure-play drug substance manufacturing facility, would be commissioned by end 2029, provided it gets all statutory clearances and environmental clearance to begin construction this October.
Show source
That would be commissioned by end 2029, provided I get all the statutory clearances and environmental clearance to begin construction this October.
- The company expects TheraNym unit two to be available for qualification by end 2029, to run PPQ batches and validation batches in 2030, and to start generating revenues in 2031 after filings and customer stockpiling for commercial launch.
Show source
But again, 2031, I expect after the filings, the customer to bid the stockpiling effort to happen for the commercial launch, which means 2031 will be when the unit two will start to generate the revenues.
Show 4 more statements
Projects and capacity
- China plant had capacity of more than 2 billion tablets, produced around 500 million plus tablets last year, and had already doubled that output in the quarter; Aurobindo plans to go beyond 2 billion tablets by the end of the year or mid of the next year.
Show source
S. Subramanian: So, the China plant, we are having a capacity of more than 2 billion tablets.
Segments
- The company has been able to produce 6-APA effectively, and its yield is in line with expectations.
Show source
We have been 6 Aurobindo Pharma Limited 06 August 2026 able to produce 6-APA also effectively and our yield is also coming out very nicely in line with our expectations.
- The company can produce 15,000 tons of 6-APA; Indian demand is around 9,000 to 10,000 tons, 5,000 tons go towards exports, and overall market demand is expected to reach around 11,000 to 12,000 tons.
Show source
The production can be easily 15,000 and the yields are very good, what is the demand overall market, which is expected to go around 11,000 to 12,000 tons.
- The company is trying to reduce third-party dependency in Canada by moving to its own captive supply of material, as it did for Europe.
Show source
Like that, we are also trying to do for Canada.
Risks, rules and outside factors
Rules and policy
- The company has filed an application for the PLI incentive, and the government will make payment in September or March, depending on the government’s policy.
Show source
Regarding the PLI incentive government, we have filed the application and they will make the payment in the month of September or March, whatever be the policy of the government, they will pay.
Everything else said on the call
Group structure
- The company completed the Lannett acquisition during the first quarter ended June 30, 2026, following FTC approval within the stipulated timelines.
Show source
A defining milestone during the quarter was the successful completion of the Lannett acquisition following FTC approval within the stipulated timelines.
- A1 Biochem, recently bought by Aurobindo Pharma Limited, has a turnover of around 100 crores.
Show source
A1 Biochem as on date is having a turnover of around 100 crores, right?
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
This transcript does not separate questions and answers, so they are not listed here.
Questions about this call
- When was the Aurobindo Pharma Q1 FY27 earnings call transcript filed?
- Aurobindo Pharma filed the transcript with the exchange on 13 Aug 2026. This page is built from that transcript.
- What does this page list?
- 39 statements from the transcript across 7 topics, 33 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- No. This transcript does not separate the questions from the answers, so they are not listed. The statements by topic still cover what management said.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.